RT Journal Article
SR Electronic
T1 Post marketing surveillance for Microwave Treatment of Plantar and Common Warts in Adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.08.22270290
DO 10.1101/2022.02.08.22270290
A1 Bristow, Ivan
A1 Joshi, Shailesh
A1 Williamson, Jonathan
A1 Ardern-Jones, Michael
YR 2022
UL http://medrxiv.org/content/early/2022/02/09/2022.02.08.22270290.abstract
AB A handheld microwave device (Swift®, Emblation Limited) has been licenced and available for clinical use since 2016 in the fields of podiatry and dermatology and has been extensively used in treating cutaneous warts. As part of post marketing surveillance by the manufacturer, an online 79-item survey was distributed to podiatry clinics in the United Kingdom with a Swift® device. A total of 126 clinics responded (59.6%). 6998 adults (<65 years) underwent wart treatment with microwave (81.9% plantar warts; 18.1% common, non-plantar warts). The median efficacy rate was reported as 79.2% (65.9 - 87.5%) and 82.3% (71.4 - 100%) respectively. In older adults (over 65 years) efficacy rates were similar for both sites: plantar (73.2%, 50-90%, n=1232) and non-plantar (80.0%, 42.1-100%, n=276). A median of three treatments was required to bring about resolution. Sub-group analysis of the data revealed good clearance rates in patients with diabetes (79.6%), but less in immunocompromised individuals (61.3%) and those with autoimmune disease (58.6%). Overall, mean user satisfaction was rated as “very satisfied” on a 10-point scale (n=93 practices). A small number of adverse events were reported including blistering, superficial ulceration and poor healing were reported (n=7). Despite the limitations of a post-marketing questionnaire survey, these data provide good evidence of the safety and efficacy for Swift® microwave treatment of cutaneous warts.What is already known about this topic?Microwave treatment has shown to be effective in the treatment of cutaneous warts.What does the study add?This survey of clinics using SWIFT microwave treatments reports on the effectiveness and safety of the device in the treatment of 8506 adult patients with common and plantar warts.Responding user clinics reporting efficacy with good clearance rates and low levels of adverse events demonstrating microwave is a safe and effective treatment for plantar and common warts.Competing Interest StatementIRB is a consultant for Emblation Limited. SJ & JW are employees of Emblation Limited.Funding StatementEmblation LimitedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The authors consulted HRA and that HRA confirmed that the present study does not require further review by REC/IRB. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors